- Welcome to Specialised Therapeutics
-
SE Asia (HQ)
+65 3158 9940
-
Australia
1300 798 820
-
New Zealand
+64 9801 0299
Resources
Australia |
Approved |
Product Information Consumer Medicine Information |
New Zealand |
Approved |
Data Sheet Consumer Medicine Information |
General |
Access Program |
Resources
Australia |
Approved |
Product Information Consumer Medicine Information |
Brunei |
Approved |
--- |
Malaysia |
Approved |
Product Information Consumer Medicine Information |
New Zealand |
Approved |
Data Sheet Consumer Medicine Information |
Philippines |
Approved |
--- |
Singapore |
Approved |
Product Information |
Thailand |
Application to be Submitted |
--- |
Vietnam |
Application to be Submitted |
--- |
General |
Healthcare Professional Information |
Resources
Australia |
Approved |
Product Information Consumer Medicine Information |
Malaysia |
Application to be Submitted |
--- |
Singapore |
Application to be Submitted |
--- |
New Zealand |
Approved |
Data Sheet Consumer Medicine Information |
General |
Access Program |
Resources
Australia |
Approved |
Product Information Consumer Medicine Information |
Brunei |
Approved |
--- |
Malaysia |
Approved |
Product Information |
Singapore |
Approved |
Product Information |
New Zealand |
Application Submitted |
--- |
Thailand |
Application to be Submitted |
--- |
Vietnam |
Application to be Submitted |
--- |
General |
Healthcare Professional Information Access Program |
Resources
Australia |
Approved |
Product Information Consumer Medicine Information |
Singapore |
Approved |
Product Information |
General |
Access Program |
Resources
Australia |
Approved |
Product Information Consumer Medicine Information |
Singapore |
Approved | Product Information |
Resources
| Anniko (penpulimab) is not yet approved for use in any of our territories. Regulatory filings are pending. |
Resources
| SKYTROFA (lonapegsomatropin) is not yet approved for use in any of our territories. Regulatory filings are pending. |
Resources
| YORVIPATH (palopegteriparatide) is not yet approved for use in any of our territories. Regulatory filings are pending. |
Resources
Australia |
Approved |
Product Information Consumer Medicine Information |
General |
Living with Multiple Myeloma: A Patient’s Story |
Resources
Australia |
Approved |
Product Information Consumer Medicine Information |
Resources
Resources
| TW001 (edaravone) is not yet approved for use in any of our territories. |
Resources
Australia |
Approved |
Product Information Consumer Medicine Information |
New Zealand |
Application Under Evaluation |
--- |
| The Oncotype DX® Breast Cancer Assay provides patients and their physicians with individualised information about their breast cancer to guide decisions on how to proceed with treatment. | More info |
